OncoMatch/Clinical Trials/NCT07020533
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Is NCT07020533 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Multi-peptide CMV-Modified Vaccinia Ankara Vaccine and Recombinant Granulocyte Colony-Stimulating Factor for accelerated phase chronic myeloid leukemia, bcr-abl1 positive.
Treatment: Letermovir · Multi-peptide CMV-Modified Vaccinia Ankara Vaccine · Recombinant Granulocyte Colony-Stimulating Factor — This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cell transplantation (haploHCT) has advanced to become the predominant procedure for patients lacking a matched donor. Compared to matched related donor transplants, the rate of significant CMV infection is higher in patients undergoing a haploHCT. Significant CMV infection is associated with an increased risk of complications and death. Vaccination is the main preventative approach to limit complications and death in immunocompromised patients at high risk of post-stem cell transplant infections. CMV-MVA Triplex vaccine, is a CMV vaccine based on the attenuated poxvirus, modified vaccinia Ankara (MVA), developed to enhance CMV-specific immunity in both healthy stem cell transplant donors and stem cell transplant patients to prevent significant CMV infection post-stem cell transplant. Giving CMV-MVA triplex vaccine may be safe, tolerable and/or effective in enhancing cytomegalovirus (CMV)-specific immunity and preventing CMV viremia in patients undergoing a haploHCT.
Check if I qualifyExtracted eligibility criteria
Cancer type
Chronic Myeloid Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Prior therapy
Cannot have received: investigational CMV vaccine
Any prior investigational CMV vaccine.
Cannot have received: experimental anti-CMV chemotherapy
Exception: within last 6 months
Experimental anti-CMV chemotherapy in the last 6 months.
Lab requirements
Kidney function
Estimated creatinine clearance acceptable per institutional guidelines (to be performed within 45 days prior to day 1 of protocol therapy)
Liver function
Total bilirubin ≤ 1.5 X ULN (unless has Gilbert's disease); AST ≤ 2.5 x ULN; ALT ≤ 2.5 x ULN (to be performed within 45 days prior to day 1 of protocol therapy)
Cardiac function
Left ventricular ejection fraction (LVEF) ≥ 50% (to be performed within 45 days prior to day 1 of protocol therapy)
Total bilirubin ≤ 1.5 X ULN (unless has Gilbert's disease); AST ≤ 2.5 x ULN; ALT ≤ 2.5 x ULN; Estimated creatinine clearance acceptable per institutional guidelines; Left ventricular ejection fraction (LVEF) ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
- Northside Hospital · Atlanta, Georgia
- Dana-Farber Cancer Institute · Boston, Massachusetts
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify